NCT06191042

A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

A Multicenter, Phase 1b, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: selectION Therapeutics GmbH · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to investigate the safety and tolerability of si-544. Other objectives are to study the metabolism of si-544 in the body and to assess the effects of si-544 on cells of the body's immune system (immune cells) that have been chronically activated by the disease. Likewise, the effect of si-544 on inflammatory responses in the body triggered by the disease and other disease symptoms will be investigated.

Conditions

• Psoriasis Vulgaris
• Psoriatic Arthritis

Interventions

Type	Name	Description
DRUG	si-544	Subcutaneous injection in the abdomen
DRUG	Placebo	Subcutaneous injection in the abdomen

Timeline

• Start date: 2024-01-22
• Primary completion: 2025-06-23
• Completion: 2025-06-23
• First posted: 2024-01-05
• Last updated: 2025-07-03

Locations

4 sites across 1 country: Germany